Welcome to our dedicated page for GENELUX SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genelux Corporation filings document the regulatory record for a clinical-stage oncology issuer developing Olvi-Vec and related immuno-oncology programs. Its disclosures include proxy statements for director elections, auditor ratification and annual meeting governance, as well as Form 8-K reports covering material agreements, Regulation FD presentations, equity financing arrangements and capital-structure updates.
The filing record also covers shelf registration and prospectus supplement activity for common stock offerings, use-of-proceeds disclosures for research and development and clinical trial expenses, and compensation matters such as outstanding option exercise-price reductions under equity incentive plans.
Pulisic Matthew reported acquisition or exercise transactions in this Form 4 filing.
GENELUX Corp Chief Financial Officer Matthew Pulisic reported an equity compensation grant of 278,906 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs were granted under the company’s 2022 Equity Incentive Plan at no cash purchase price.
Each RSU represents the right to receive one share of common stock upon vesting. According to the award terms, 25% of the RSUs will vest on the first anniversary of the grant date, with the remaining RSUs vesting in 12 equal quarterly installments thereafter. Following this grant, Pulisic’s directly held common stock reported in this filing totals 278,906 shares.
Groen Eric reported acquisition or exercise transactions in this Form 4 filing.
GENELUX Corp granted General Counsel Eric Groen 233,957 restricted stock units (RSUs) of common stock as equity compensation. The RSUs were awarded at no cash cost to Groen and represent a contingent right to receive shares upon vesting.
The grant was made under the company’s 2022 Equity Incentive Plan. 25% of the RSUs will vest on the first anniversary of the grant date, with the remaining units vesting in 12 equal quarterly installments over the following three years, subject to the vesting conditions.
Cappello Joseph reported acquisition or exercise transactions in this Form 4 filing.
GENELUX Corp Chief Technical Officer Joseph Cappello received a grant of 174,841 restricted stock units (RSUs). These RSUs were awarded at no purchase price under the company’s 2022 Equity Incentive Plan and increase his directly owned common stock and RSU holdings to 329,390 shares.
The award vests over time, with 25% of the RSUs vesting on the first anniversary of the grant date. The remaining 75% will vest in 12 equal quarterly installments, aligning Cappello’s compensation with longer-term company performance and continued service.
GENELUX Corp director James L. Tyree reported equity awards from the company. He received 28,409 shares of common stock in the form of restricted stock units, which each convert into one share of common stock when they vest. After this grant, he directly holds 96,483 shares of common stock.
Tyree was also granted stock options for 31,566 shares of common stock at an exercise price of $3.03 per share, expiring on June 15, 2036. Both the RSUs and the options vest on the earlier of the one-year anniversary of the June 16, 2026 grant date or the company’s next annual meeting of stockholders.
GENELUX Corp reported that President and CEO Thomas Zindrick received a grant of 730,601 restricted stock units (RSUs) of common stock as equity compensation. The award was made at no cash cost per share under the company’s 2022 Equity Incentive Plan.
Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest 25% on the first anniversary of the grant date, with the remaining units vesting in 12 equal quarterly installments thereafter. Following this grant, Zindrick directly holds 1,263,913 shares of common stock, which includes 1,261 shares acquired through the Employee Stock Purchase Plan on May 15, 2026.
GENELUX Corp director Thomas John reported new equity awards rather than open-market trades. He received 28,409 shares of common stock in the form of restricted stock units, each representing one share upon vesting. He was also granted stock options for 31,566 shares at an exercise price of $3.03 per share, expiring on June 15, 2036. Both the RSUs and the options will vest on the earlier of one year from the June 16, 2026 grant date or the company’s next annual stockholder meeting. Following these awards, John directly holds 501,193 shares of GENELUX common stock.
GENELUX Corp director Mary Mirabelli reported equity awards that increase her stake in the company. She received 28,409 shares of common stock in the form of restricted stock units granted under the 2022 Equity Incentive Plan, bringing her direct holdings to 102,693 common shares.
She was also granted stock options for 31,566 shares of common stock at an exercise price of $3.03 per share, expiring on June 15, 2036. Both the RSUs and options vest upon the earlier of one year from grant or the next annual meeting of stockholders, making this a compensation-related, non-market acquisition rather than an open-market trade.
Yu Yong reported acquisition or exercise transactions in this Form 4 filing.
GENELUX Corp Chief Scientific Officer Yu Yong received an equity award of 119,318 restricted stock units. These RSUs were granted at no cash cost under the company’s 2022 Equity Incentive Plan, increasing his directly held common stock–equivalent position to 269,024 shares, assuming full vesting.
The award vests over time: 25% will vest on the first anniversary of the grant date, with the remaining RSUs vesting in 12 equal quarterly installments thereafter. This structure is designed to tie a significant portion of the executive’s compensation to the company’s long-term share performance and ongoing service.
GENELUX Corp director John W. Smither reported equity awards consisting of restricted stock units and stock options. He received 28,409 shares of Common Stock as a grant, bringing his directly held Common Stock to 103,403 shares following the award.
Smither was also granted stock options covering 31,566 shares of Common Stock at an exercise price of $3.03 per share, expiring on June 15, 2036. Both the restricted stock units and the options vest upon the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders.
GENELUX Corp executive Ralph Smalling, Head of Regulatory, reported an open-market sale of 192 shares of common stock at $2.93 per share on June 3, 2026. According to the footnote, these shares were sold solely to cover estimated taxes owed upon the vesting of restricted stock units. After this tax-related sale, Smalling directly held 67,611 shares of GENELUX common stock.